CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental
arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will
be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy.